

1. (Currently Amended) A method for the prediction of response to cancer treatment, ~~by the detection of at least 2 markers characterized in that the markers are genes and fragments thereof or genomic nucleic acid sequences that are located on one chromosomal region which is altered in malignant neoplasia~~ comprising:
amplifying a nucleic acid sequence in a sample of a patient and
detecting at least 4 markers in the nucleic acid sequence, wherein
the at least 4 markers comprise polynucleotides comprising SEQ ID NO:
361, SEQ ID NO: 363, SEQ ID NO: 379, SEQ ID NO: 392.

2. (Original) The method of claim 1 wherein the treatment is an antibody treatment, antihormonal treatment, anti-growth factor treatment, taxol based treatment, anthracyclin based treatment and platinum salt based treatment.

3. (Original) The method of claim 1 wherein the treatment includes Herceptin™, trastuzumab or 2C4 antibodies.

4. (Canceled)

5. (Currently Amended) The method of claim 1 ~~or 2~~ wherein the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.

6. (Canceled)

7. (Currently Amended) A method for the ~~prediction, diagnosis or prognosis~~ of malignant neoplasia ~~by the detection of~~ said method comprising:

amplifying a nucleic acid sequence in a sample of a patient and

~~detecting~~ at least four markers in the nucleic acid sequence ~~one~~
~~marker~~ characterized in that the ~~marker is~~ four markers are selected
 from:

(a) ~~a polynucleotide or polynucleotide analog comprising at least~~
~~one of the sequences of SEQ ID NO: 319 to 389~~ polynucleotides
comprising SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379, and SEQ ID
NO: 392;

(b) a polynucleotide or polynucleotide analog which hybridizes
 under stringent conditions to a polynucleotide specified in (a) and
 encodes a polypeptide exhibiting the same biological function as
 specified for the respective sequence in Table 2 or 3

(c) a polynucleotide or polynucleotide analog the sequence of
 which deviates from the polynucleotide specified in (a) and ~~(e~~ b) due
 to the generation of the genetic code encoding a polypeptide
 exhibiting the same biological function as specified for the
 respective sequence in Table 2 or 3

(d) a polynucleotide or polynucleotide analog which represents a
 specific fragment, derivative or allelic variation of a polynucleotide
 sequence specified in (a) to ~~(d~~ c)

(e) a purified polypeptide encoded by a polynucleotide or
 polynucleotide analog sequence specified in (a) to ~~(e~~ d)

(f) ~~e purified polypeptide~~ polypeptides encoded by SEQ ID NO: 361,
SEQ ID NO: 363, SEQ ID NO: 379, and SEQ ID NO: 392 ~~comprising at~~
~~least one of the sequences of SEQ ID NO: 397 - 467;~~

~~Are detected.~~

8. - 9. Canceled

10. (New) A diagnostic kit for detecting markers SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379 and SEQ ID NO: 392, said kit comprising polynucleotides which are complementary to a portion of the coding sequence of SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 379 and SEQ ID NO: 392.